Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar
<p dir="ltr">Duchenne Muscular Dystrophy is a rare, X-linked neuromuscular disorder that leads to progressive muscle degeneration, loss of ambulation, and premature mortality due to respiratory and cardiac failure. Historically, Duchennke Muscular Dystrophy has been managed through s...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513521280090112 |
|---|---|
| author | Mahmoud Fawzi Osman (23770893) |
| author2 | Khalid Ibrahim (3853360) Claire Gleeson (23770896) Haytham Ibrahim (21406778) Ikram Ul Haque (23770899) Noora Alhamad (6187880) Tawfeg Ben-Omran (6663634) |
| author2_role | author author author author author author |
| author_facet | Mahmoud Fawzi Osman (23770893) Khalid Ibrahim (3853360) Claire Gleeson (23770896) Haytham Ibrahim (21406778) Ikram Ul Haque (23770899) Noora Alhamad (6187880) Tawfeg Ben-Omran (6663634) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mahmoud Fawzi Osman (23770893) Khalid Ibrahim (3853360) Claire Gleeson (23770896) Haytham Ibrahim (21406778) Ikram Ul Haque (23770899) Noora Alhamad (6187880) Tawfeg Ben-Omran (6663634) |
| dc.date.none.fl_str_mv | 2025-11-27T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1038/s41434-025-00580-3 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Real-world_experience_with_gene_therapy_in_Duchenne_muscular_dystrophy_center_readiness_and_patients_safety_report_from_Qatar/32075520 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Genetics Biomedical and clinical sciences Neurosciences Paediatrics Pharmacology and pharmaceutical sciences Duchenne Muscular Dystrophy (DMD) Neuromuscular disorder Gene therapy Pediatric neurology Rare diseases Clinical outcomes |
| dc.title.none.fl_str_mv | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Duchenne Muscular Dystrophy is a rare, X-linked neuromuscular disorder that leads to progressive muscle degeneration, loss of ambulation, and premature mortality due to respiratory and cardiac failure. Historically, Duchennke Muscular Dystrophy has been managed through supportive and symptomatic treatments, with limited options for disease modification. However, advancements in gene therapy have introduced promising interventions aimed at addressing the underlying dystrophin deficiency. Delandistrogene moxeparvovec (Elevidys) received accelerated approval from the U.S. Food and Drug Administration in June 2023 for ambulatory children aged 4–5 years with a confirmed diagnosis of Duchenne Muscular Dystrophy. This approval represented an advancement, offering a disease-modifying therapy at an early stage when muscle function remains relatively preserved. The Food and Drug Administration expanded its approval in June 2024 to include both ambulatory and non-ambulatory children aged 4 years and older. This study provides a retrospective real-world analysis of eight Duchenne Muscular Dystrophy patients who received Elevidys gene therapy at our center in Qatar. Recognizing the complexities involved in treating older Duchenne Muscular Dystrophy patients, a standardized protocol for pre- and post-infusion care was implemented. Our findings highlight the positive clinical outcomes of gene therapy for Duchenne Muscular Dystrophy patients in Qatar.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Gene Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41434-025-00580-3" target="_blank">https://dx.doi.org/10.1038/s41434-025-00580-3</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_cf08bce4901857fc172882d19f82ace8 |
| identifier_str_mv | 10.1038/s41434-025-00580-3 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/32075520 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from QatarMahmoud Fawzi Osman (23770893)Khalid Ibrahim (3853360)Claire Gleeson (23770896)Haytham Ibrahim (21406778)Ikram Ul Haque (23770899)Noora Alhamad (6187880)Tawfeg Ben-Omran (6663634)Biological sciencesGeneticsBiomedical and clinical sciencesNeurosciencesPaediatricsPharmacology and pharmaceutical sciencesDuchenne Muscular Dystrophy (DMD)Neuromuscular disorderGene therapyPediatric neurologyRare diseasesClinical outcomes<p dir="ltr">Duchenne Muscular Dystrophy is a rare, X-linked neuromuscular disorder that leads to progressive muscle degeneration, loss of ambulation, and premature mortality due to respiratory and cardiac failure. Historically, Duchennke Muscular Dystrophy has been managed through supportive and symptomatic treatments, with limited options for disease modification. However, advancements in gene therapy have introduced promising interventions aimed at addressing the underlying dystrophin deficiency. Delandistrogene moxeparvovec (Elevidys) received accelerated approval from the U.S. Food and Drug Administration in June 2023 for ambulatory children aged 4–5 years with a confirmed diagnosis of Duchenne Muscular Dystrophy. This approval represented an advancement, offering a disease-modifying therapy at an early stage when muscle function remains relatively preserved. The Food and Drug Administration expanded its approval in June 2024 to include both ambulatory and non-ambulatory children aged 4 years and older. This study provides a retrospective real-world analysis of eight Duchenne Muscular Dystrophy patients who received Elevidys gene therapy at our center in Qatar. Recognizing the complexities involved in treating older Duchenne Muscular Dystrophy patients, a standardized protocol for pre- and post-infusion care was implemented. Our findings highlight the positive clinical outcomes of gene therapy for Duchenne Muscular Dystrophy patients in Qatar.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Gene Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41434-025-00580-3" target="_blank">https://dx.doi.org/10.1038/s41434-025-00580-3</a></p>2025-11-27T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1038/s41434-025-00580-3https://figshare.com/articles/journal_contribution/Real-world_experience_with_gene_therapy_in_Duchenne_muscular_dystrophy_center_readiness_and_patients_safety_report_from_Qatar/32075520CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/320755202025-11-27T09:00:00Z |
| spellingShingle | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar Mahmoud Fawzi Osman (23770893) Biological sciences Genetics Biomedical and clinical sciences Neurosciences Paediatrics Pharmacology and pharmaceutical sciences Duchenne Muscular Dystrophy (DMD) Neuromuscular disorder Gene therapy Pediatric neurology Rare diseases Clinical outcomes |
| status_str | publishedVersion |
| title | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| title_full | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| title_fullStr | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| title_full_unstemmed | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| title_short | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| title_sort | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar |
| topic | Biological sciences Genetics Biomedical and clinical sciences Neurosciences Paediatrics Pharmacology and pharmaceutical sciences Duchenne Muscular Dystrophy (DMD) Neuromuscular disorder Gene therapy Pediatric neurology Rare diseases Clinical outcomes |